Welcome to LookChem.com Sign In|Join Free
  • or
4-(tert-Butyldimethylsilanyloxymethyl)-2,6-dimethyl-phenol is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

452369-73-2

Post Buying Request

452369-73-2 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

452369-73-2 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 452369-73-2 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 4,5,2,3,6 and 9 respectively; the second part has 2 digits, 7 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 452369-73:
(8*4)+(7*5)+(6*2)+(5*3)+(4*6)+(3*9)+(2*7)+(1*3)=162
162 % 10 = 2
So 452369-73-2 is a valid CAS Registry Number.

452369-73-2Downstream Products

452369-73-2Relevant academic research and scientific papers

LIPID PRODRUGS OF NEUROSTEROIDS

-

Paragraph 00584; 00586, (2021/08/13)

The present invention provides lymphatic system-directing lipid prodrugs, pharmaceutical compositions thereof, methods of producing such prodrugs and compositions, as well as methods of improving the bioavailability or other properties of a therapeutic agent that comprises part of the lipid prodrug. The present invention also provides methods of treating a disease, disorder, or condition such as those disclosed herein, comprising administering to a patient in need thereof a disclosed lipid prodrug or a pharmaceutical composition thereof.

LIPID PRODRUGS OF GLUCOCORTICOIDS AND USES THEREOF

-

Paragraph 00638; 00640, (2020/09/12)

The present invention provides lymphatic system-directing lipid prodrugs, pharmaceutical compositions thereof, methods of producing such prodrugs and compositions, and methods of improving the bioavailability or other properties of a therapeutic agent that comprises part of the lipid prodrug. The present invention also provides methods of treating a disease, disorder, or condition such as those disclosed herein, comprising administering to a patient in need thereof a disclosed lipid prodrug or a pharmaceutical composition thereof.

LIPID PRODRUGS OF PREGNANE NEUROSTEROIDS AND USES THEREOF

-

Paragraph 00471; 00473, (2020/02/23)

The present invention provides lymphatic system-directing lipid prodrugs, pharmaceutical compositions thereof, methods of producing such prodrugs and compositions, as well as methods of improving the bioavailability or other properties of a therapeutic agent that comprises part of the lipid prodrug. The present invention also provides methods of treating a disease, disorder, or condition such as those disclosed herein, comprising administering to a patient in need thereof a disclosed lipid prodrug or a pharmaceutical composition thereof.

LIPID PRODRUGS OF JAK INHIBITORS AND USES THEREOF

-

Paragraph 00645; 00647, (2020/09/12)

The present invention provides lymphatic system-directing lipid prodrugs, pharmaceutical compositions thereof, methods of producing such prodrugs and compositions, and methods of improving the bioavailability or other properties of a therapeutic agent that comprises part of the lipid prodrug. The present invention also provides methods of treating a disease, disorder, or condition such as those disclosed herein, comprising administering to a patient in need thereof a disclosed lipid prodrug or a pharmaceutical composition thereof.

LIPID PRODRUGS OF BTK INHIBITORS AND USES THEREOF

-

Paragraph 00405; 00654; 00656, (2020/09/12)

The present invention provides lymphatic system-directing lipid prodrugs, pharmaceutical compositions thereof, methods of producing such prodrugs and compositions, and methods of improving the bioavailability or other properties of a therapeutic agent that comprises part of the lipid prodrug. The present invention also provides methods of treating a disease, disorder, or condition such as those disclosed herein, comprising administering to a patient in need thereof a disclosed lipid prodrug or a pharmaceutical composition thereof.

NOVEL ACYLATING REAGENTS

-

Page 25, (2008/06/13)

Novel acylating agents useful for preparing activated nucleophiles such as terminally activated polymers are disclosed. In preferred aspects, the acylating agents are formula (I) and formula (II) and they used to prepare activated polymers such as PEG's f

Terminally-branched polymeric linkers and polymeric conjugates containing the same

-

, (2008/06/13)

Terminally-branched polymeric prodrug platforms capable of high degrees of loading are disclosed. In preferred aspects of the invention, the prodrug platform releases multiple parent compounds after each branch holding the active agent undergoes a benzyl

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 452369-73-2